Literature DB >> 27202180

Simulation Model of Ibrutinib in Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL).

S Peng1, S Sorensen1, F Pan1, E Dorman1, S Sun2, S Van Sanden3, N Sengupta4, M Gaudig5.   

Abstract

Entities:  

Year:  2014        PMID： 27202180     DOI： 10.1016/j.jval.2014.08.2196

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  3 in total

Review 1.  Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.

Authors:  Esther S Kim; Sohita Dhillon
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

Review 2.  Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Paul Tappenden; Emma Simpson; Jean Hamilton; Daniel Pollard; Mark Clowes; Eva Kaltenthaler; David Meiklejohn; Nick Morley
Journal:  Pharmacoeconomics       Date:  2019-03       Impact factor: 4.981

3.  Differential B-Cell Receptor Signaling Requirement for Adhesion of Mantle Cell Lymphoma Cells to Stromal Cells.

Authors:  Laia Sadeghi; Gustav Arvidsson; Magali Merrien; Agata M Wasik; André Görgens; C I Edvard Smith; Birgitta Sander; Anthony P Wright
Journal:  Cancers (Basel)       Date:  2020-05-02       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.